Novo Nordisk expects lack of Wegovy doses to continue until H2 2022

Issues at a sub-contractor have meant that Novo Nordisk only has a limited supply of obesity drug Wegovy in its lowest doses available until the second half of 2022. (Corrected)

Photo: Stine Tidsvilde

(Corrected at 9:40 to clarify the extent of the supply issues)

In the first half of 2022, Novo Nordisk will only be able to meet demand for the the lowest initial doses of weight loss treatment Wegovy to a limited extent, an update from the Danish company's US-based subsidiary reports on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs